Key result
CCTA refines risk stratification for nonobstructive CAD but its impact on clinical outcomes remains unproven.
Why the study?
Nonobstructive coronary artery disease is frequently detected by CCTA, but compresses biologically distinct patterns into a single anatomic label.
Does coronary CT angiography improve phenotyping and risk stratification in patients with nonobstructive coronary artery disease?
Does coronary CT angiography improve phenotyping and risk stratification in patients with nonobstructive coronary artery disease?
CCTA is evolving into a multidimensional phenotyping tool for nonobstructive coronary artery disease, offering refined risk stratification, though prospective outcome studies are needed.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Cardiology is undergoing a transition now from a pure focus on identifying patients with obstructive CAD and treating them aggressively, [sometimes] after they've had an MI, to moving sooner [due to] realizing that nonobstructive CAD is not benign—and that it is heterogeneous and that it is common and undertreated”
Supports CCTA phenotyping in nonobstructive CAD; leaves open outcome impact and clinical adoption pending prospective trials.
Purpose of review Nonobstructive coronary artery disease (NOCA) is now frequently detected by coronary CT angiography (CCTA), but the term compresses biologically distinct patterns into a single anatomic label. This review examines how CT-derived markers can reorganize NOCA around plaque burden, inflammatory activity, clinical expression, and temporal change. Recent findings Recent work distinguishes three related but distinct tasks in NOCA: identify disease, stratify risk, and define phenotypes that may inform future prevention strategies. CCTA addresses the atherosclerotic and prognostic dimensions by quantifying plaque burden, plaque composition, and high-risk features; CT-derived inflammatory and cardiometabolic markers may further identify active vascular and metabolic phenotypes. In symptomatic patients, CCTA and fractional flow reserve CT can evaluate epicardial anatomy and lesion-specific hemodynamic significance, but normal or nonobstructive findings do not exclude coronary microvascular dysfunction or vasospasm. In asymptomatic patients, coronary artery calcium and CCTA can reveal subclinical atherosclerosis and refine preventive risk assessment. Serial imaging and intervention studies suggest that adverse plaque phenotypes can stabilize or change with intensive prevention, but outcome-proven CCTA-guided treatment algorithms are still lacking. Summary CCTA is evolving into a multidimensional phenotyping tool for NOCA. Its immediate value is refined risk stratification; whether these markers will improve outcomes remains unproven and should be tested prospectively.
No takes yet. Share an insight, caveat, or question.
Piña et al. (2026) conducted a review in Nonobstructive coronary artery disease (NOCA). Coronary CT angiography (CCTA) was evaluated. Coronary CT angiography provides multidimensional phenotyping and refined risk stratification for nonobstructive coronary artery disease, though its impact on clinical outcomes remains unproven.
Synapse has enriched 10 related papers. Consider them for comparative context: